AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00998699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xoma 052
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Study NCT00998699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution subcutaneously administered every 4 weeks for 12 weeks
Study NCT00750802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2mg tablet, oral single-dose
Study NCT00750802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02634073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
Study NCT02634073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorbitol
Description: It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
Study NCT02764008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml %0,25 bupivacaine
Study NCT02764008 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Study NCT01531465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary Function Testing & esophageal pressure monitoring
Description: Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
Study NCT01531465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pulmonary function testing and esophageal pressure
Description: Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
Study NCT03445195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam-ETX2514
Description: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Study NCT03445195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 1g IV solution.
Study NCT03445195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Imipenem-cilastatin
Description: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
Study NCT03445195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Description: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
Study NCT04677062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-328
Description: Patients with GV-328 treatment
Study NCT03199248 — intervention group
Intervention type: PROCEDURE
Intervention: Aspiration with percutaneous capsulotomy For digital mucous cysts
Description: The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
Study NCT05375500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telemedicine digital therapeutic
Description: digital therapeutics intervention for chronic pain utilizing coaching and virtual reality application
Study NCT00918983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1207
Description: Single intraprostatic injection of 2.5 mg NX-1207
Study NCT00918983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of placebo
Study NCT03212040 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: needle biopsy
Description: breast biopsy using different needle gauges
Study NCT02765152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
Study NCT02765152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discrete movement training group
Description: Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
Study NCT02765152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic movement training group
Description: Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
Study NCT03118934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
Study NCT03118934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nelfilcon A multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
Study NCT03118934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A multifocal contact lenses
Description: Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
Study NCT04536662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: The initial dose of hydrocortisone (20mg/tablet) was 15mg/m2/day to the maximum dose of 60mg, which was orally administered in three times, with the dose ratio of 2:1:3, and the administration time was 8:00-15:00-21:00.
Study NCT04536662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The initial dose of prednisone (5mg/tablet) was 3mg/m2/day to the maximum dose of 15mg. The dosage ratio was 1:2 and the administration time was 8:00 and 21:00.
Study NCT04536662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: The initial dose of dexamethasone (0.75mg/tablet) was 0.3mg/m2/day to the maximum dose of 0.75mg and the administration time was 21:00.
Study NCT01668836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1 pill daily containing 500 mg/d of resveratrol for 30 days
Study NCT01668836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Diet of 1000kcal per day for 30 days
Study NCT00972959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
Study NCT00972959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
Study NCT00972959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
Study NCT03625726 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Thrombin generation assay (in vitro)
Description: One blood sample.
Study NCT03625726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombin generation assay (in vitro)
Description: One blood sample.
Study NCT03016169 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trifecta GT (Glide Technology) Valve
Description: Surgical aortic valve replacement with Trifecta GT Valve.
Study NCT00908765 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 1. High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~2. Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
Study NCT03351712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-Based Intervention and Activity Tracker WITH Feedback
Description: Combining ACT and Behavioral Change
Study NCT03351712 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gold Standard Intervention + Activity Tracker WITHOUT Feedback
Description: Medical Rehabilitation, Motivational Support and Psycho-Education
Study NCT03351712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Standard Intervention and Activity Tracker WITH Feedback
Description: Behavioral Change Condition - Activity Tracker
Study NCT03351712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-Based Intervention and Activity Tracker WITHOUT Feedback
Description: ACT-Based Intervention Standalone
Study NCT04552613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: (A) Standard programme group, EGFR-TKI targeted therapy;
Study NCT04552613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGFR-TKI combined with chemotherapy (pemetrexed plus carboplatin)
Description: (B) controlled programme group, EGFR-TKI targeted therapy combined chemotherapy(pemetrexed plus carboplatin for 4 cycles )
Study NCT00721409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
Study NCT02977793 — intervention group
Intervention type: DEVICE
Intervention: Tomey EM-4000 Specular Microscope
Study NCT02977793 — intervention group
Intervention type: DEVICE
Intervention: Konan CellChek XL Specular Microscope
Study NCT03169790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03169790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study NCT03169790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
Study NCT03169790 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)
Study NCT03169790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03169790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1\[MUC1\]
Study NCT03169790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion
Study NCT03248882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03248882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05221304
Description: PF-05221304, Experimental Drug
Study NCT01656200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis vaccine SA14-14-2
Description: Live attenuated Japanese encephalitis vaccine SA14-14-2
Study NCT01457482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy and therapeutic conversations
Description: Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
Study NCT00721409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg/d tablets orally on a continuous regimen
Study NCT02400801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: gonadotropin-releasing hormone (GnRH) agonist
Study NCT02400801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol + dienogest
Description: oral oestroprogestogen
Study NCT01098084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/day, one hour intravenous infusion, every day during 5 days
Study NCT02033759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio-Impedance Testing
Description: Participants in the BIA Arm will also undergo bio-impedance testing with this device.
Study NCT02033759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety Questionnaire
Description: 21 item questionnaire
Study NCT02033759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Questionnaire
Description: 21 item questionnaire
Study NCT02033759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Circumferential Measurements
Study NCT02033759 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Circumferential Measurements
Study NCT01162733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 15mg/kg
Study NCT01162733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 30mg/kg
Study NCT01457482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic conversations
Description: Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
Study NCT03412201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
Study NCT03412201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Care
Description: Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
Study NCT05045651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gender Solution®posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA and standard posterior stabilized NexGen® LPS Hi-Flex; Zimmer Biomet, Inc, Warsaw, IN, USA
Description: gender specific knee prosthesis:design for female to restore Q-angle, reduce anteroposterior (AP)/mediolateral(ML) ratio for reducing overhang of femoral component, increase valgus angle of trochlea groove, and reduce thickness of anterior part of prosthesis for prevention overstuff with patella. The standard TKA or unisex knee prosthesis was design for female and male.
Study NCT03864198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Genante
Description: A dietary supplement for male infertility
Study NCT00656708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kerlix AMD gauze
Description: Use Kerlix AMD gauze as the wound dressing for the entire burn unit
Study NCT02252770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitric oxide supplement
Description: Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
Study NCT02252770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will not contain nitric oxide supplement.
Study NCT03582527 — intervention group
Intervention type: OTHER
Intervention: all study participants
Description: patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
Study NCT00873028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Hospital Cardiopulmonary Rehabilitation
Description: The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
Study NCT03858829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric analysis
Description: Psychometric analysis
Study NCT03374449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuation of the RAS-inhibitors
Description: drug intake
Study NCT03374449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: discontinuation of the RAS-inhibitors
Description: no drug intake
Study NCT03435913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard PEEP ventilation
Description: During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
Study NCT03435913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matched PEEP ventilation
Description: During mechanical ventilation PEEP is matched to IAP level
Study NCT02950610 — intervention group
Intervention type: DEVICE
Intervention: Breath analysis - electronic signature Breath-print
Description: Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
Study NCT04326322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methionine Intake
Description: Intakes will be randomly chosen from a list of 7 doses of methionine. Each intake will will be repeated approximately 5 times.
Study NCT03400111 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
Study NCT03400111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panadol-extra
Description: Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
Study NCT04680195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months.